Libtayo (Cemiplimab)
cemiplimab 350 mg/7 mL injection, 7 mL vial · INJECTION · PBS code 13159N
AUTHORITY_REQUIREDWhat it costs
AU$7290 PBS-determined price per pack
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2022-11-01.
- • Repeats: 7.
- • PBS program: IP.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC)
Continuing treatment
Patient must have previously received PBS-subsidised therapy with this drug for this condition; AND
The treatment must be the sole PBS-subsidised therapy for this condition; AND
Patient must not be undergoing treatment with this drug as a PBS benefit where the treatment duration extends beyond the following, whichever comes first: (i) disease progression despite treatment with this drug, (ii) 24 months from treatment initiation; annotate any remaining repeat prescriptions with the word 'cancelled' where this occurs.
Sponsor: MEDISON PHARMA AUSTRALIA PTY LIMITED ABN 19 659 723 403
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.